Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation

Journal of Cardiovascular Medicine

Volumn 9, Issue 4, 2008, Pages 410-413

  Eshtehardi, Parham ^a   Eslami, Masoud ^a   Moayed, Davood Akhlagh ^a,b  

^a Pars General Hospital Tehran   (Iran)

^b NONE   (Iran)

Author keywords

Cardiogenic shock; Coronary stent thrombosis; Drug eluting stent; Factor V Leiden; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANGIOPLASTY; BALLOON DILATATION; CARDIOGENIC SHOCK; CASE REPORT; DRUG ELUTING STENT; FOLLOW UP; GENE MUTATION; HOSPITAL READMISSION; HUMAN; HYPERCOAGULABILITY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RIGHT CORONARY ARTERY; THROMBOSIS;

ANGIOPLASTY, BALLOON; ANTICOAGULANTS; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FACTOR V; HUMANS; MALE; MIDDLE AGED; MUTATION; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; SIROLIMUS; TICLOPIDINE; WARFARIN;

EID: 40649106537     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282eee98b     Document Type: Review

References (22)

1. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al., e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434-1441.
2. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020-1029.
3. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967-1971.
4. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26:1180-1187.
5. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496-501.
6. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947-953.
7. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126:1304-1318.
8. Dahlback B. The discovery of activated protein C resistance. J Thromb Haemost 2003; 1:3-9.
9. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506.
10. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522.
11. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis [letter]. Thromb Haemost 1994; 72:647.
12. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-917.
13. Lindblad B, Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C [letter]. Lancet 1994; 343:917.
14. Holm J, Zoller B, Svensson PJ, Berntorp E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344:952-953.
15. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease [letter]. Lancet 1995; 345:526.
16. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73:558-560.
17. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [letter]. Lancet 1995; 345:321.
18. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75:701-702.
19. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100:3-10.
20. Siscovick DS, Schwartz SM, Rosendaal FR, Psaty BM. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78:7-12.
21. Santos JL, Cruz I, Martin Herrero F, Albarran C, Gonzalez Matas JM, Martin Luengo C. Recurrent coronary thrombosis, factor V Leiden, primary antiphospholipid syndrome and HIV [in Spanish]. Rev Esp Cardiol 2004; 57:997-999.
22. Marcucci R, Brogi D, Sofi F, Giglioli D, Valente S, Lotta AA, et al. PAI-1 and homocysteine but not lipoprotein(a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 2006; 92:377-381.